Cardiodiabetology: Evolution or Revolution?

Q: What does this research mean for the field?

Modern diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, have evolved to provide significant cardioprotective benefits, including the management of cardiovascular risks and arrhythmias in patients with type 2 diabetes. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

I. Z. Bondarenko; V. Y. Kalashnikov

doi:10.14341/dm13295

February 1, 2025Diabetes MellitusOpen Access

Cardiodiabetology: Evolution or Revolution?

View Full Paper

Ask AI

Bookmark

Share

Why the study?

The article addresses contemporary issues in endocrine cardiology by analyzing the history and cardiovascular effects of diabetes medications, from early insulins to modern cardioprotective agents.

Structured PICO

P

Population

Patients with type 2 diabetes mellitus (T2DM)

I

Intervention

Diabetology medications including sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and insulins

Implication

This review summarizes the evolution of diabetes therapies into cardiodiabetology, emphasizing the cardiovascular benefits and anti-arrhythmic potential of SGLT2 inhibitors and GLP-1 receptor agonists.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bondarenko et al. (2025) studied this question.

synapsesocial.com/papers/6a1d2549ba65f5ee325de338 https://doi.org/10.14341/dm13295

Topics

SGLT2 inhibitors in heart failure

GLP-1 agonists cardiovascular outcomes

View Full Paper

Ask AI

Bookmark

Share

Cardiodiabetology: Evolution or Revolution?

Structured PICO

Implication

Discussion

Cite This Study

Topics

Cardiodiabetology: Evolution or Revolution?

Structured PICO

Implication

Discussion

Cite This Study

Keep reading

Topics

Keep reading